Candel Therapeutics Inc (NASDAQ: CADL) kicked off on Monday, up 6.64% from the previous trading day, before settling in for the closing price of $5.57. Over the past 52 weeks, CADL has traded in a range of $4.25-$13.68.
During the last 5-year period, the sales drop of Healthcare Sector giant was -43.86%. While this was happening, its average annual earnings per share was recorded 76.06%. With a float of $41.06 million, this company’s outstanding shares have now reached $54.90 million.
Candel Therapeutics Inc (CADL) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 25.21%, while institutional ownership is 36.98%. The most recent insider transaction that took place on Jul 28 ’25, was worth 6,540. In this transaction Chief Medical Officer of this company sold 937 shares at a rate of $6.98, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Chief Medical Officer sold 781 for $5.04, making the entire transaction worth $3,936. This insider now owns 52,493 shares in total.
Candel Therapeutics Inc (CADL) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.23 earnings per share (EPS), higher than consensus estimate (set at -0.23) by -0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 76.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 35.44% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Take a look at Candel Therapeutics Inc’s (CADL) current performance indicators. Last quarter, stock had a quick ratio of 8.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.56, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.99 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Looking closely at Candel Therapeutics Inc (NASDAQ: CADL), its last 5-days average volume was 0.8 million, which is a drop from its year-to-date volume of 0.97 million. As of the previous 9 days, the stock’s Stochastic %D was 19.75%.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 64.24%, which indicates a significant increase from 63.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.46 in the past 14 days, which was higher than the 0.33 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.25, while its 200-day Moving Average is $5.62. However, in the short run, Candel Therapeutics Inc’s stock first resistance to watch stands at $6.24. Second resistance stands at $6.53. The third major resistance level sits at $6.93. If the price goes on to break the first support level at $5.55, it is likely to go to the next support level at $5.15. Now, if the price goes above the second support level, the third support stands at $4.86.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
The company with the Market Capitalisation of 326.10 million has total of 54,898K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -55,180 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -11,270 K.
